Integrating toxicogenomics into human health risk assessment: Lessons learned from the benzo[a]pyrene case study

Critical Reviews in Toxicology

Volumn 45, Issue 1, 2015, Pages 44-52

  Chepelev, Nikolai L ^a,b   Moffat, Ivy D ^a,b   Labib, Sarah ^a   Bourdon Lacombe, Julie ^a   Kuo, Byron ^a   Buick, Julie K ^a   Lemieux, France ^a   Malik, Amal I ^a   Halappanavar, Sabina ^a   Williams, Andrew ^a   Yauk, Carole L ^a,b  

^a HEALTH CANADA   (Canada)

^b Environmental Health Centre Ottawa   (Canada)

Author keywords

Benchmark dose; Carcinogens; Dose response; Environmental pollutant; Genotoxicity; Mode of action; Point of departure; Polycyclic aromatic hydrocarbon

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN;

CASE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; EXPERIMENTAL DESIGN; GENE EXPRESSION; GENOMICS; HEALTH HAZARD; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; TOXICITY TESTING; TOXICOGENETICS; ANIMAL; CHEMICALLY INDUCED; NEOPLASM; PROCEDURES;

ANIMALIA;

ANIMALS; BENZO(A)PYRENE; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS; RISK ASSESSMENT; TOXICITY TESTS; TOXICOGENETICS;

EID: 84921486205     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2014.973935     Document Type: Review

References (40)

1. Allen BC, Strong PL, Price CJ, Hubbard SA, Daston GP. (1996). Benchmark dose analysis of developmental toxicity in rats exposed to boric acid. Fundam Appl Toxicol, 32, 194-204.
2. Auerbach SS, Shah RR, Mav D, Smith CS, Walker NJ Vallant MK, et al. (2010). Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 243 : 300-314.
3. Black MB, Parks BB, Pluta L, Chu TM, Allen BC, Wolfinger RD, Thomas RS, et al. (2014). Comparison of microarrays and RNA-seq for gene expression analyses of dose-response experiments. Toxicol Sci, 137, 385-403.
4. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36 : 781-792.
5. Bourdon JA, Williams A, Kuo B, Moffat I, White PA, Halappanavar S, et al. (2013). Gene expression profiling to identify potentially relevant disease outcomes and support human health risk assessment for carbon black nanoparticle exposure. Toxicology, 303C, 83-93.
6. Daston GP, Naciff JM. (2010). Predicting developmental toxicity through toxicogenomics. Birth Defects Res C Embryo Today, 90, 110-7.
7. Elferink MG, Olinga P, Draaisma AL, Merema MT, Bauerschmidt S, Polman J, et al. (2008). Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Toxicol Appl Pharmacol, 229, 300-9.
8. Gold LS, Manley NB, Slone TH, Ward JM. (2001). Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol Pathol, 29, 639-52.
9. Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J, et al. (2010). Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov 9, 435-445.
10. Hill A. (1965). THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?. Proc R Soc Med 58 : 295-300.
11. IARC (International Agency for Research on Cancer). (2012). A review of human carcinogens: Chemical agents and related occupations. IARC Monogr Eval Carcinog Risks Hum 100F, 111-44.
12. Jackson AF, Williams A, Recio L, Waters MD, Lambert IB, Yauk CL. (2014). Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan. Toxicol Appl Pharmacol, 274, 63-77.
13. Lemieux C, Douglas G, Gingerich J, Phonethepswath S, Torous DK, Dertinger SD, et al. (2011). Simultaneous measurement of benzo[a] pyrene-induced Pig-a and lacZ mutations, micronuclei and DNA adducts in Muta ™ (Mouse. Environ Mol Mutagen, 52, 756-65.
14. Li H, Qiu J, Fu XD. (2012). RASL-seq for massively parallel and quantitative analysis of gene expression. Curr. Protoc. Mol. Biol. 98 : 4.13.1-4.13.9.
15. Li H-H, Hyduke DR, Chen R, Heard P, Aubrecht J, Fornace AJ Jr. (2014). Development of a toxicogenomics signature for genotoxicity using a dose-optimization and informatics strategy in human cells. (submitted to Toxicol. Sci.) xxx-xxx.
16. Lin WJ, Hsueh HM, Chen JJ. (2010). Power and sample size estimation in microarray studies. BMC Bioinformatics, 11, 48.
17. Lobenhofer EK, Cui X, Bennett L, Cable PL, Merrick BA, Churchill GA, Afshari CA, et al. (2004). Exploration of low-dose estrogen effects: Identification of No Observed Transcriptional Effect Level (NOTEL). Toxicol Pathol, 32, 482-92.
18. Mathijs K, Brauers KJ, Jennen DG, Boorsma A, van Herwijnen MH, Gottschalk RW, et al. (2009). Discrimination for genotoxic and nongenotoxic carcinogens by gene expression profiling in primary mouse hepatocytes improves with exposure time. Toxicol Sci., 112, 374-84.
19. Meek ME. (2008). Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ Mol Mutagen, 49, 110-6.
20. Meek ME, Klaunig JE. (2010). Proposed mode of action of benzeneinduced leukemia: Interpreting available data and identifying critical data gaps for risk assessment. Chem Biol Interact, 184, 279-85.
21. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-653.
22. Meek ME, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. (2014). Mode of action human relevance (species concordance) framework: Eevolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol 34(6) : 595-606.
23. Moffat ID, Chepelev NL, Labib S, Bourdon-Lacombe J, Kuo B, Buick JK. et al. (2014). Comparison of toxicogenomics and traditional approaches in quantitative risk assessment of benzo(a)pyrene for drinking water. Crit Rev Toxicol 45, 1-43.
24. NRC (National Research Council). (2007b). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press.
25. OECD. (Organisation for Economic Co-operation and Development). (2012a). Guidance document 116 on the conduct and design of chronic toxicity and carcinogenicity studies, supporting test guidelines 451, 452 and 453. 2nd edition. Available at from: http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=ENV/JM/MONO(2011)47&doclanguage=en. Accessed on August August 1, 2013.
26. OECD. (2012b). Proposal for a template, and guidance on developing and assessing the completeness of adverse outcome pathways. Available from: http://www.oecd.org/env/ehs/testing/49963554.pdf. Accessed on August 12, 2013.
27. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, et al. (2006). The MicroArray Quality Control (MAQC) project shows interand intraplatform reproducibility of gene expression measurements. Nat Biotechnol, 24, 1151-61.
28. Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol 34, 146-52.
29. Steinhoff C, Vingron M. (2006). Normalization and quantification of differential expression in gene expression microarrays. Brief Bioinform, 7, 166-77.
30. Thomas RS, Clewell HJ III, Allen BC, Yang L, Healy E, Andersen ME, et al. (2012). Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: A five chemical case study. Mutat Res, 746, 135-43.
31. Thomas RS, Allen BC, Nong A, Yang L, Bermudez E, Clewell HJ III, Andersen ME, et al. (2007). A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci., 98, 240-28.
32. Thomas RS, Clewell HJ III, Allen BC, Wesselkamper SC, Wang NC, Lambert JC, et al. (2011). Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci., 120, 194-205.
33. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci., 136, 4-18.
34. US EPA. (2012). Benchmark dose technical guidance 2012. Available from: http://www.epa.gov/osa/raf/publications/benchmark-dose-guidance.pdf. Accessed on August 28, 2013.
35. US EPA. (2005). Guidelines for carcinogen risk assessment 2012. Available from: http://www.epa.gov/cancerguidelines/. Accessed on August 28, 2013.
36. US EPA (2011). Integrated Risk Information System (IRIS) Glossary. Available from: http://www.epa.gov/ncea/iris/index.html. Accessed on May 13, 2014.
37. van Delft JH, Mathijs K, Staal YC, van Herwijnen MH, Brauers KJ, Boorsma A, Kleinjans JC, et al. (2010). Time series analysis of benzo[A]pyrene-induced transcriptome changes suggests that a network of transcription factors regulates the effects on functional gene sets. Toxicol Sci., 117, 381-92.
38. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, et al. (2006). Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics, 7, 59.
39. Yauk CL, Berndt ML. (2007). Review of the literature examining the correlation among DNA microarray technologies. Environ Mol Mutagen, 48, 380-94.
40. Yauk CL, Bishop J, Dearfield KL, Douglas GR, Hales BF, Luijten M, et al. (2013). The development of adverse outcome pathways for mutagenic effects for the organization for economic co-operation and development. Environ Mol Mutagen, 54, 79-81.